HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Has 18.2% OTC Drug Sales Increase In Hand, But Not Decision On Talc Business Bankruptcy Plan

Executive Summary

J&J reported worldwide consumer health and personal care product Q3 sales up 4.1% to $3.7bn driven by 18.2% increase in OTC drug sales. Excluding OTC, its consumer business results would have been down as sales for all other sectors slipped.

You may also be interested in...



J&J Without Consumer Health? Tylenol, Band-Aid Marketer Plans To Divest Business In Two Years

“As we watch the health care landscape continue to evolve, we think that it's only incumbent upon us to think about what kind of an impact that should have on our portfolio,” says CEO Alex Gorsky. The dependable revenue driver with iconic consumer health brands will be separated from J&J’s Rx drug and medical device division as a standalone, publicly traded company.

J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible

Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.

J&J Cosmetic Talc Lawsuits Halted, $2Bn Trust Created, As Subsidiary Takes Liabilities Into Bankruptcy

Johnson & Johnson’s newly created subsidiary LTL Management LLC will take all cosmetic talc injury claims against the Johnson’s Baby Powder manufacturer into bankruptcy proceedings. J&J says the move is designed to ensure “equitable” resolution for all parties, while plaintiff’s attorneys have a decidedly different view on the matter.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS151858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel